Abstract
In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Current Medicinal Chemistry
Title: Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Volume: 9 Issue: 13
Author(s): F. Manetti, F. Corelli, G. Strappaghetti and M. Botta
Affiliation:
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Abstract: In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Export Options
About this article
Cite this article as:
Manetti F., Corelli F., Strappaghetti G. and Botta M., Arylpiperazines with Affinity Toward a1-Adrenergic Receptors, Current Medicinal Chemistry 2002; 9 (13) . https://dx.doi.org/10.2174/0929867023369961
DOI https://dx.doi.org/10.2174/0929867023369961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design Green Aqueous Synthesis of Mono, Bis and Trisdihydropyridines Using Nano Fe<sub>3</sub>O<sub>4</sub> Under Ultrasound Irradiation
Current Organic Synthesis Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke
Current Neurovascular Research Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets
Current Drug Metabolism Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of Fexofenadine for Ulcerative Colitis
Current Drug Delivery Rosuvastatin and Diabetes: When the Evidences Talk
Cardiovascular & Hematological Agents in Medicinal Chemistry Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Ischemic Neuronal Damage
Current Pharmaceutical Design Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design Evaluation of Antidiabetic Activity of <i>Rosmarinus officinalis var. prostratus</i> Growing in Syria in Alloxan Diabetic Rats
Current Bioactive Compounds Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients
Current Pharmaceutical Design Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Current Vascular Pharmacology Antioxidants in Peripheral Arterial Disease
Current Drug Targets Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Catecholaminergic Strategies for the Treatment of Major Depression
Current Drug Targets